Introduction: Despite many efforts to improve the outcome of pancreatic ductal
adenocarcinoma (PDAC), its prognosis remains poor, which is mostly related to late …

Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis
because of its aggressive character, late-stage diagnosis, and resistance against systemic …

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death in
the Western world. Owing to a lack of specific symptoms and no accessible precursor …

Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-
related deaths in the Western world. Due to lack of specific symptoms and no accessible …

In the past decade, insightful preclinical research has led to important breakthroughs in our
understanding of pancreatic cancer. Even though the vast majority of pancreatic cancers are …

Pancreatic ductal adenocarcinoma (PDAC) is an incidence rate nearly equal to its mortality
rate. The poor prognosis of the disease can be explained by the absence of effective …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is diagnosed
at the locally advanced or metastatic stage in approximately 80% of cases. Relative to other …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor with high lethality. Even
with surgery, radiotherapy, chemotherapy, and other locoregional or systemic therapies, the …

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal types of cancer in the
United States. Surgical resection remains the only curative treatment, but fewer than 20% of …

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy projected to
be the 2nd leading cause of cancer related death in the USA by 2030. This manuscript …